AET, or Alpha-Ethyltryptamine, is a synthetic compound that belongs to the tryptamine class, known for its unique blend of psychedelic and entactogenic properties. It shares structural similarities with compounds like DMT and αMT but differs significantly in its effect profile. Originally developed in the 1960s as a potential antidepressant, AET has since found niche use among researchers and psychonauts for its ability to facilitate emotional introspection, enhance sensory perception, and induce mild euphoria without overwhelming hallucinations.

• Chemical classification and structure
  AET is part of the tryptamine family, featuring an indole ring connected to an ethylated amine group. This structure is closely related to that of serotonin, allowing AET to interact with the brain’s serotonin receptors.

• Originally developed for therapeutic use
  Pharmaceutical companies explored AET in the 1960s as an antidepressant. It was seen as promising due to its mood-elevating effects without major sedation or stimulation.

• Dual-action properties
  AET acts both as a serotonin releasing agent and a receptor agonist. This dual mechanism results in empathogenic effects and subtle changes in perception and cognition.

• Noted for emotional clarity and empathy
  Unlike more dissociative psychedelics, AET fosters a sense of emotional presence and warmth, often compared to MDMA in terms of social comfort.

• Subtle psychedelic effects
  While not as visually intense as LSD or psilocybin, AET can still produce mild visuals, sensory enhancement, and thought pattern shifts, especially at higher doses.

• Gained popularity in underground circles
  After being discontinued pharmaceutically, AET became a sought-after compound among research communities and underground psychonauts.

• Used in contemporary research settings
  In modern studies and self-directed exploration, AET is prized for its balanced profile—providing insight without overwhelming intensity.

The effects of AET are often described as emotionally enriching, gently euphoric, and socially expansive. Unlike some psychedelics that disconnect users from their surroundings, AET tends to heighten connection—both internal and interpersonal—while keeping cognition relatively intact. Its effects are often viewed as a cross between MDMA’s warmth and psilocybin’s introspective clarity, with fewer visual distortions and a more manageable duration.

• Enhanced emotional sensitivity
  Users frequently report a deepened ability to reflect on personal feelings, experiences, and memories without defensiveness or fear, which is valuable for therapeutic-style research.

• Mild euphoria and mood elevation
  AET elevates mood in a smooth and sustained way, avoiding the intense spikes of more stimulating compounds. This gentle euphoria is described as organic and grounded.

• Increased sociability and empathy
  Verbal communication feels easier, more sincere, and fluid under AET. This makes it particularly suitable for studies involving group dynamics or emotional bonding.

• Sensory enhancement
  Sounds, especially music, are perceived as richer and more immersive. Tactile sensations may feel heightened, leading to increased body awareness or comfort.

• Mild closed-eye visuals
  At moderate to high doses, some users report intricate, dreamlike visuals with closed eyes. These are typically soft and geometric rather than vivid or chaotic.

• Preserved cognitive function
  Unlike high-dose psychedelics, AET generally allows users to maintain coherent thought and speech, making it suitable for analytical or verbal tasks during sessions.

• Afterglow effect
  Following the primary experience, many users feel emotionally lighter, clearer, and at peace—sometimes lasting into the next day without a “comedown” crash.

AET requires careful dosing due to its dose-sensitive effects. Lower doses often produce mild stimulation and emotional uplift, while higher doses bring on more pronounced entactogenic and psychedelic features. Because individual body chemistry can affect response, it’s essential to start conservatively and monitor reactions before increasing the dose.

• Threshold dose: 25–50 mg
  At this level, users may notice subtle changes in mood, body energy, and awareness. Ideal for microdosing or introductory tests.

• Light dose: 50–100 mg
  Produces noticeable emotional openness, light stimulation, and mild sensory enhancement without overwhelming effects.

• Common dose range: 100–150 mg
  Standard range for full research experiences, typically yielding a blend of euphoria, empathy, and light psychedelic visuals.

• High dose: 150–200+ mg
  Can induce stronger body load, overstimulation, and cognitive disorganization. Recommended only for experienced researchers.

• Oral administration is standard
  AET is usually taken in capsule or dissolved form. Oral consumption ensures a smoother onset and longer duration.

• Onset within 30–60 minutes
  Timing can vary depending on stomach contents and individual metabolism. A light meal before dosing may help reduce nausea.

• Avoid redosing
  Redosing can prolong the experience but often increases side effects like jaw tension or anxiety. Best to wait until full effects subside before reconsidering.

The legal status of AET varies widely across countries and regions. While it may not be explicitly scheduled in many jurisdictions, its structural similarity to other controlled substances can subject it to analog or blanket laws. Before acquiring or researching AET, it’s critical to verify its legality in your specific location.

• Not scheduled in many jurisdictions
  AET is often absent from national drug schedules, which technically makes it legal to possess or sell—depending on the country.

• Subject to analog laws in the U.S.
  In the United States, AET may be prosecuted under the Federal Analog Act if deemed “substantially similar” to a scheduled substance like αMT.

• Controlled in select countries
  Countries like the United Kingdom, Australia, and parts of Europe may classify AET under broad psychoactive substance bans or specific analog acts.

• Psycho Plug’s labeling policy
  We clearly mark AET as “Not for human consumption” and “For research purposes only” to comply with regulatory guidelines.

• Responsibility falls on the buyer
  Buyers must understand and accept the risks of importing or possessing AET in regions where laws are unclear or in flux.

• Confiscation or seizure risk
  While rare, customs authorities may seize packages based on suspicion or misclassification. We offer refund or reshipment options in such cases.

• Always verify with local laws
  Consult official government listings, local attorneys, or researchers familiar with chemical import laws before placing an order.

Proper storage of AET is essential to maintaining its chemical integrity, potency, and usability over time. Exposure to light, moisture, or extreme temperatures can degrade the compound, which may compromise its research validity or make it unsafe for further use. Following best practices ensures both safety and longevity.

• Store in a cool, dark place
  Temperature-controlled environments such as cabinets, closets, or coolboxes protect AET from heat-related breakdown.

• Use airtight, moisture-proof containers
  Oxygen and humidity are primary threats to chemical stability. Vacuum-sealed bags or lab-grade jars with desiccants are ideal.

• Avoid exposure to sunlight
  UV light can break down tryptamines over time. Use opaque or amber-colored containers to shield AET from harmful rays.

• Keep away from volatile chemicals
  AET should not be stored near acidic, alkaline, or reactive materials which might cause unwanted interactions.

• Label clearly and securely
  All containers should include product name, date received, and purity level to ensure easy tracking and responsible handling.

• Store away from children or unauthorized users
  Always keep AET in a secure location, preferably locked or coded, especially in shared households.

• Optional: Refrigeration
  While not necessary for short-term storage, refrigeration (not freezing) can extend shelf life further, especially in humid climates.

While AET is considered to have a favorable safety profile when used in controlled research environments, it is not without risks. The compound’s interaction with serotonin pathways means it must be treated with care, especially when combined with other serotonergic substances. Comprehensive harm reduction practices should always be followed during any research involving AET.

• Low physical toxicity at standard doses
  Animal studies and anecdotal human reports suggest that AET has low physical toxicity when used at responsible research doses (50–150 mg). However, individual sensitivity can vary significantly.

• Risk of serotonin syndrome
  AET is a serotonin releaser, meaning that combining it with SSRIs, MAOIs, or other serotonergic compounds can result in serotonin syndrome—a potentially dangerous condition characterized by agitation, fever, muscle rigidity, or seizures.

• Psychological risks for vulnerable individuals
  AET may exacerbate symptoms in individuals with underlying mental health conditions, such as anxiety, bipolar disorder, or schizophrenia. Caution is advised in any research involving psychologically sensitive populations.

• Mild side effects may include nausea and jaw tension
  Common but typically transient side effects include light nausea during the onset, slight muscle tension (especially in the jaw), and occasional headaches during the comedown.

• Overstimulation possible at high doses
  Doses above 150 mg may result in excessive stimulation, anxiety, or a sense of restlessness. Higher doses can also increase heart rate and blood pressure.

• Short-term tolerance development
  AET builds rapid short-term tolerance, meaning it should not be used on consecutive days. A 7–14 day interval is advised between sessions to maintain effectiveness and reduce physical stress.

• Lack of long-term clinical research
  While anecdotal reports describe AET as relatively benign, long-term data is lacking. Therefore, extended or repeated use should be approached conservatively.

AET and MDMA share several similarities—most notably, their capacity to enhance empathy, mood, and emotional expression. However, their mechanisms of action, intensity, and risk profiles differ significantly. Understanding these distinctions can help researchers choose the appropriate compound for their specific use case.

• AET is less stimulating than MDMA
  Unlike MDMA, which produces a significant increase in energy and euphoria, AET’s effects are more subtle and introspective. It does not produce the same physical rush or overwhelming body high.

• Longer, gentler onset
  AET typically takes 30–60 minutes to begin working, compared to MDMA’s 20–40 minutes. Its onset is smoother, resulting in fewer abrupt emotional shifts.

• Visual and cognitive enhancement
  AET offers light visual distortions and a more dreamlike cognitive state, whereas MDMA rarely causes perceptual changes. This makes AET closer to a psychedelic, though much milder than LSD or psilocybin.

• Lower neurotoxicity risk
  MDMA has been shown to cause neurotoxic effects in animal studies after high or repeated dosing. AET lacks the same volume of study, but anecdotal evidence suggests a more favorable neurochemical safety profile when used sparingly.

• Greater focus on introspection
  While MDMA enhances external social interaction, AET encourages reflection and personal insight. This makes it valuable in research focused on internal emotional processes.

• Lower impact on the cardiovascular system
  AET generally produces less of an increase in heart rate and blood pressure than MDMA, which can be a concern in certain populations or long sessions.

• Legal ambiguity versus strict scheduling
  MDMA is a tightly controlled Schedule I drug in many countries. AET, while not widely legal, is often not explicitly scheduled, offering more flexibility for researchers.

Though not approved for clinical use, AET shows significant potential in therapeutic settings, particularly for emotional processing and trauma exploration. Its ability to foster openness, empathy, and emotional insight makes it a promising candidate for further investigation in psychedelic-assisted therapy frameworks.

• Encourages emotional transparency
  AET allows individuals to access deeply held emotions without overwhelming anxiety or fear, which is crucial in trauma and grief-focused therapy.

• Facilitates cognitive reprocessing
  The compound appears to support re-evaluation of past events with greater compassion and clarity, making it a useful tool for therapeutic dialogue.

• Reduced risk of overactivation
  Compared to more intense psychedelics like psilocybin or ayahuasca, AET has a gentler onset and manageable intensity, making it safer for novice participants or those with high emotional reactivity.

• Shorter duration fits modern therapy sessions
  AET’s 4–8 hour window allows for same-day integration and minimal interference with daily schedules, unlike longer-acting psychedelics such as LSD.

• Minimal sensory overload
  Its mild visual and physical effects ensure that sessions remain grounded, helping clients stay focused on emotional and verbal processing rather than navigating hallucinations.

• Less body load than MDMA
  MDMA’s heavy stimulation and temperature fluctuation can be exhausting for clients. AET’s lower body load can result in smoother sessions with less physical fatigue.

• Requires more clinical research
  While anecdotal reports are positive, AET is not yet part of any FDA-approved therapy program. All use should be strictly experimental and under controlled conditions.

AET’s historical path is marked by early pharmaceutical ambition, mid-century obscurity, and modern revival among niche research communities. Its development was initially tied to antidepressant research, but it later found a second life in underground exploration and experimental science.

• Discovered in the 1960s by Upjohn Pharmaceuticals
  AET was synthesized and investigated for its potential as a mood elevator and antidepressant, offering an alternative to monoamine oxidase inhibitors (MAOIs) and tricyclics of the time.

• Early research discontinued due to side effects
  Despite initial promise, clinical development was halted due to mild overstimulation and the risk of abuse, especially when higher doses were administered.

• Resurfaced in the underground psychedelic scene
  In the 1980s and 1990s, AET began circulating in experimental circles and was reviewed favorably in underground psychedelic literature, including notes from researchers like Alexander Shulgin.

• Became part of the “research chemical” wave
  As online communities emerged in the 2000s, AET gained a reputation as a rare but valuable compound for its unique effect profile, sitting somewhere between entactogens and psychedelics.

• Not widely studied in formal literature
  Despite over 50 years of knowledge, AET has been largely absent from academic journals or formal medical trials, limiting its data availability compared to LSD or MDMA.

• Still legally ambiguous in many countries
  Unlike substances that have been formally banned by international treaties, AET remains unclassified in many parts of the world, allowing for low-scale research and commerce.

• Continues to intrigue modern psychonauts
  Today, AET is valued for its therapeutic potential, low intensity, and rare presence. It’s one of the lesser-known gems of the tryptamine family.

While AET is generally considered safe when handled responsibly, like all psychoactive research chemicals, it carries a number of potential physical and psychological risks. Awareness and preparation are essential to minimizing adverse reactions.

• Overstimulation and anxiety at high doses
  Doses above 150 mg may lead to jitteriness, racing thoughts, or a sense of unease, especially in sensitive individuals or noisy environments.

• Cardiovascular strain
  Although mild, AET can raise heart rate and blood pressure, which may pose a concern for users with preexisting heart conditions.

• Nausea and gastrointestinal discomfort
  Common during onset, nausea is usually short-lived but may be intensified by taking AET on a full stomach or under physical stress.

• Jaw tension and muscle clenching
  Some users report tension in the jaw, neck, or shoulders—similar to MDMA. Magnesium supplements may help mitigate this effect.

• Serotonin depletion with repeated use
  Because AET acts on serotonin systems, using it too frequently can lead to mood dips or emotional flatness afterward. Proper spacing between sessions is critical.

• Potential for psychological destabilization
  Those with a history of mental illness should avoid AET unless under professional guidance, as it can trigger latent anxiety or emotional flooding.

• Unknown long-term effects
  Due to limited clinical studies, there is little data on AET’s impact after long-term or repeated use. It should be treated as a powerful tool, not a casual substance.

The duration of AET’s effects is a key factor in its appeal for both researchers and psychonauts. It provides a well-balanced window of action—long enough to explore its full spectrum of effects without becoming overwhelming or disruptive to daily functioning. Understanding the timeline of its onset, peak, and comedown allows for better session planning and safer integration into experimental protocols.

• Onset typically begins within 30–60 minutes
  After oral ingestion, most users begin to notice mood elevation, body awareness, and perceptual changes within the first hour. This slow climb helps reduce anxiety and prepares the user for the peak.

• Peak effects occur between 1.5–3 hours post-dose
  During the peak, AET reaches full potency, delivering emotional clarity, enhanced sensory perception, and in some cases, mild visuals. This is the most introspective and immersive part of the experience.

• Primary duration lasts 4–8 hours
  The overall experience can vary depending on dose, metabolism, and environment, but the majority of effects resolve within this window, making it suitable for same-day integration.

• Afterglow may continue for 1–2 hours
  After the primary effects subside, users often experience residual warmth, clarity, and mental calm, sometimes called the “afterglow.” This state is typically free of stimulation or fatigue.

• Return to baseline by 8–10 hours
  Full mental and physical baseline is usually restored within 10 hours, though some may notice slightly altered thought patterns or sleep changes if used late in the day.

• Low residual stimulation
  Unlike compounds like LSD or 2C-B, AET does not typically cause lingering overstimulation, making it easier to eat, sleep, or relax afterward.

• Ideal for structured research sessions
  The total arc of the AET experience aligns well with standard therapy or lab timeframes, offering ample time for deep work without requiring multi-day recovery.

AET is not considered physically addictive, but any substance that alters mood or consciousness can carry a risk of psychological dependence if misused. While it lacks the chemical reward loops of stimulants or opioids, responsible and intentional use remains critical to avoiding unhealthy patterns.

• No physical withdrawal symptoms
  AET does not produce cravings or withdrawal effects upon cessation, even after repeated use. This sets it apart from habit-forming substances like benzodiazepines or alcohol.

• Low potential for tolerance buildup
  Like many tryptamines, AET exhibits short-term tolerance, meaning that its effects diminish when used on consecutive days. This natural tolerance helps discourage compulsive use.

• Psychological dependency possible
  Individuals using AET as a form of emotional escape or to cope with life stressors may begin to rely on the substance for relief, especially if used without intentional structure.

• Gentle euphoria can be reinforcing
  The positive mood and emotional openness AET provides may be tempting to revisit frequently, especially for users struggling with isolation or trauma.

• Best used with clear intent
  Incorporating journaling, session planning, and rest periods between uses can help maintain a healthy relationship with AET and prevent compulsive patterns.

• Spacing sessions maintains potency
  Allowing at least 7–14 days between sessions not only preserves AET’s effectiveness but also minimizes emotional blunting or burnout.

• No known compulsive behaviors triggered
  AET does not activate reward pathways in the same way as substances of abuse, such as cocaine or amphetamines, lowering its misuse potential in most populations.

Combining AET with other compounds should be approached with extreme caution. While some users experiment with synergies to modulate or enhance effects, AET’s interaction with serotonin makes it risky to combine with many common medications and supplements. In general, it’s safest to research AET on its own.

• Avoid all serotonergic medications
  Combining AET with SSRIs, SNRIs, MAOIs, or tricyclic antidepressants may significantly increase serotonin levels, risking serotonin syndrome, a potentially life-threatening condition.

• Cannabis may increase intensity
  Some users report that low-dose cannabis enhances AET’s visual and emotional effects, but others experience anxiety or confusion. Results vary widely depending on dose and individual sensitivity.

• Benzodiazepines reduce intensity
  Sedatives like diazepam or clonazepam can be used to manage anxiety or end difficult experiences, but they also dull AET’s therapeutic benefits and may reduce memory of the session.

• Alcohol is not recommended
  Alcohol can increase dehydration, reduce self-control, and interfere with memory formation during AET sessions. Combining the two may also strain the liver.

• Other psychedelics may lead to unpredictable results
  Stacking AET with substances like LSD, psilocybin, or 2C compounds can produce chaotic or overwhelming experiences due to overlapping receptor activity and stimulation.

• Stimulants increase cardiovascular risk
  Combining AET with amphetamines or other stimulants may raise blood pressure and heart rate to dangerous levels. This is especially risky for individuals with heart issues.

• Best practice is to use AET in isolation
  For safety, clarity of results, and personal insight, AET should ideally be used alone and in a well-prepared setting with access to emergency care if needed.

While AET is primarily known for its emotional and empathogenic effects, it can also produce a range of mild to moderate visual alterations. These visuals are typically more aesthetic and soft than those associated with classic psychedelics like LSD or DMT.

• Subtle enhancements of color and contrast
  Colors may appear more vivid or saturated, and shadows or light sources may seem more pronounced or beautiful. This enhancement contributes to the emotional richness of the experience.

• Light tracers and motion blur
  Moving objects may leave behind faint trails, especially in dim lighting. This can create a dreamy, slowed-down effect that enhances music or conversation.

• Geometric patterns with eyes closed
  With eyes closed, users may see gentle, flowing shapes or mandala-like patterns. These visuals are typically not intense or fractal-like but are calming and meditative.

• Altered depth perception
  Distances may seem slightly exaggerated or compressed, giving a sense of dimensional richness to the environment.

• Textural distortions
  Surfaces like walls or fabrics may appear to shimmer or ripple slightly. These effects are usually gentle and do not impair function.

• Visuals are dose-dependent
  At lower doses (50–75 mg), visuals are minimal or absent. At higher doses (125–150 mg+), they become more noticeable but rarely intrusive or overwhelming.

• No hallucinations in the classical sense
  AET does not typically produce fully formed, autonomous visual entities or scenes like those seen with DMT. Visual effects remain grounded in the real world and are best described as enhancements rather than hallucinations.

Microdosing AET is a lesser-known but growing practice among individuals seeking subtle cognitive and emotional enhancement without full-blown psychedelic effects. While formal studies are lacking, anecdotal reports suggest AET may offer benefits similar to low-dose psilocybin or LSD, with a distinct entactogenic character.

• Typical microdose ranges from 5 to 15 mg
  At these low levels, AET generally does not produce perceptual alterations, but users often report elevated mood, improved focus, and increased sociability.

• Used once every 3–5 days
  Due to its mild tolerance-building effect, most protocols recommend spacing doses several days apart to avoid diminishing returns.

• Supports emotional resilience
  Microdosing AET may help users navigate daily stressors with greater patience, empathy, and emotional clarity—especially in social or work settings.

• Low impact on energy levels
  Unlike stimulant microdoses, AET does not usually cause jitteriness or restlessness, making it a gentler option for daily function.

• Minimal disruption to routine
  Because AET microdoses do not impair coordination or judgment, many users can continue regular tasks such as working, exercising, or driving (though caution is always advised).

• Potential alternative to SSRI medication
  Some individuals have explored AET microdosing as a way to manage low-grade depression or emotional flatness, though this should never replace professional medical guidance.

• Not officially studied or endorsed
  All microdosing with AET remains experimental. Anyone considering this should consult a medical professional and keep detailed records of their experiences for safety and insight.